~~<i id='23C478E81B'><strike id='23C478E81B'><tt id='23C478E81B'><pre id='23C478E81B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：explore 2025-08-28 08:47:08 - browse：2

Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

Read on for brief explanations of what we’re watching for from each company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Medicare drug price negotiation hasn't dried up venture capital

Wikipedia

focus

entertainment

focus

leisure time

Understandhowscience,healthpolicy,andmedicineshapetheworldeveryday.SignupforourMorningRoundsnewslett

WSS

FDA warns J&J's Abiomed: We will regulate your software

Medicare drug price negotiation hasn't dried up venture capital

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Keeping primary care docs in field isn't impossible, says AAFP CEO

Solve the antibiotic resistance crisis with preventive drugs

Can sheer will power keep patients alive in their dying hours?

hotspot

explore

Wikipedia

Cancer drug shortages should be causing more outrage

David Ricks of Eli Lilly: best biopharma CEO of 2023

The high cost of giving birth even with insurance

Readout Newsletter: The latest on Moderna, Apellis, and Merck

BioMarin wins approval for gene therapy to treat hemophilia A

Studies point to risks of excluding people with obesity from drug trials

Medicare proposal to cover medical devices draws a mixed reaction

Editas, Vertex strike deal on CRISPR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Beam Therapeutics to lay off 20% of its staff, re

focus

What STAT readers think about the FDA and patient advocacy

2023 STAT Wunderkinds: get to know the winners

Prime Medicine, Myeloid Therapeutics clash over genome

CRISPR gene editing developments we’re watching in 2024

Impact of Dobbs ruling felt at reproductive medicine meeting

Hospitals owned by private equity see complications spike 25%

entertainment

focus

focus

leisure time